A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
Clinical trial NCT05120960 · WITHDRAWN
Trial details
- NCT number
- NCT05120960
- Sponsor
- M.D. Anderson Cancer Center
- Status
- WITHDRAWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-27
- Primary completion
- 2024-04-12
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.